Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

Sanofi refocuses COVID-19 efforts away from mRNA

Trial data validates Sanofi’s mRNA and lipid nanoparticle platform but the company will not pursue its own mRNA COVID-19 vaccine

Biogen Idec building

Rolling submission granted for Biogen/Eisai’s next Alzheimer’s antibody

The FDA will review the data for Biogen and Eisai’s anti-amyloid beta protofibril antibody, lecanemab, on an ongoing basis

- PMLiVE

Innovative Trials named Best global Patient Recruitment Company of 2021

Innovative Trials, has been named Best Global Patient Recruitment Company by the Healthcare & Pharmaceutical Awards 2021.

Innovative Trials

- PMLiVE

Public is more comfortable with health data sharing if they know it is to support breakthrough treatments and vaccines

By Andrew Harrison

Our mission: helping patients in areas of unmet medical need

Oxford PharmaGenesis

- PMLiVE

Novo Nordisk settles US insulin pricing dispute for $100m

Novo Nordisk admits no liability or wrongdoing but will pay investors $100m to “avoid the burden, inherent risk and expense of further litigation”

- PMLiVE

Mysterious big pharma company eyes US biotech Acceleron

Speculation is running high that a major pharma company will make a move on Massachusetts-based pulmonary and haematology biotech Acceleron this week

- PMLiVE

COVID-19 changed change and communications will never be the same

By Chris Bath

- PMLiVE

Understanding behaviour change: A Porterhouse Insights specialism

At Porterhouse Insights, we help pharmaceutical and healthcare companies understand the changes in behaviour needed to make better healthcare choices.To promote a change in a certain behaviour, we must first...

Porterhouse Medical Group

- PMLiVE

Lynparza significantly delays disease progression as first-line treatment in prostate cancer

New data show AstraZeneca and Merck‘s PARP inhibitor, Lynparza, delayed disease progression as a first-line treatment in advanced prostate cancer

Biogen Idec building

Rocky start for Biogen’s Alzheimer’s drug Aduhelm

Controversial Alzheimer’s treatment Aduhelm is struggling to realise its potential, with only 100 patients receiving the therapy so far in the US

Changing human behaviour forever through software – only if humans allow

By David Williams

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links